Category: Analyst’s Comments

SeaSpine Holdings Corporation (SPNE) stock has seen a decrease of 14.32% in the aftermarket. However, the last trading session closed at $16.34 with an incline of 0.68%. Cantor Virtual Global Healthcare Conference It is announced on 22 September 2021 that SPNE will speak at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021, at 8:00 a.m. ET. Moreover, the event will be streamed live and archived on the Company’s Investor Relations Website at investor.seaspine.com. SPNE will Host Analyst & Investor Event On 16th September 2021, SPNE reported that on Thursday, September 30th, from 7:30 a.m. to 8:45 a.m.

Universal Security Instruments, Inc. (UUU) stock has experienced a decline of 7.87% in the aftermarket. However, the last trading session closed at $5.59 with an increase of 1.64%. UUU Reports First Quarter Results On 19th August 2021, UUU stock released its financial results for the fiscal quarter that ended on June 30, 2021. Sales grew by 58.7% to $4,667,998 for the quarter ending June 30, 2021, compared to $2,940,768 for the same time the previous year. The company earned $14,641 in net income or $0.01 per basic and diluted share. Despite continued supply chain and transportation cost difficulties, UUU is

StealthGas Inc. (GASS) stock has seen a decline of 18.95% in the premarket. However, the last trading session concluded at $2.55 with a decrease of 0.39%. Second Quarter 2021 Financial results by GASS GASS reported second-quarter 2021 results on 25th August 2021. Revenues for the three months ended June 30, 2021, were $39.2 million, up to $2.9 million or 8.0 percent from $36.3 million in the same period last year. This owed to the addition of six vessels now operating in the spot market or under a time charter contract, which were previously used on bareboat charters. Voyage expenditures and

vTv Therapeutics Inc. (VTVT) has skyrocketed in the aftermarket by experiencing an increase of 15.82%. This increase was observed after VTVT announced the results of the Multiple Ascending Dose Study and Development Plan for HPP737. However, the last trading session concluded at $1.77 with an incline of 4.12%. Results of Multiple Ascending Dose Study and Development Plan for HPP737 VTVT announced the results of the multiple ascending dose studies on 23rd September 2021. HPP737 was evaluated in healthy people in a multiple ascending dosage trial. Twelve individuals received HPP737 or a placebo. Dose escalation up to 20mg/day resulted in dose

BEST Inc. (BEST), a smart supply chain service provider, has seen an increase of 5.92% in the premarket trading session. As a consequence, the BEST stock is trading at $1.79 at the time of writing. On Wednesday, BEST stock closed the day at $1.69 after increasing 4% during regular hours. The reason for this rise according to some is the interest of Redditors in the stock. They are buying BEST stock massively. For the moment, let’s discuss recent developments related to BEST stock. Q2 2021 financial results On 18th August, BEST reported the quarterly results for the second quarter of the fiscal

Senmiao Technology Ltd. (AIHS), a company engaged in the automobile transaction and related services business, has seen an increase of 8.41% in the premarket trading session. Consequently, AIHS stock is trading at $0.77 at the time of this writing. On Wednesday, AIHS stock gained 25.99% in regular trading hours and closed the day at $0.71. This continuous rising trajectory is due to the intensive buying from short term investors. Such a short term trend could lead to a decline in AIHS stock during the next few months. Let’s have some discussion about recent developments of AIHS stock. AIHS announced operating

Grindrod Shipping Holdings Ltd (GRIN) stock prices were down by 4.85% as of the market closing on September 22nd, 2021. This brought the price per share down to USD$15.70 at the end of the trading day. Subsequent premarket fluctuations saw the stock dip by 4.46%, bringing it down to USD$15.00. GRIN Stock Prices Offering September 22nd, 2021 saw GRIN stock announce the pricing of its previously announced underwritten public secondary offering. The offering will see the sale of 1,841,962 ordinary shares by certain existing shareholders of the company. Each share will have a public offering price of USD$13.50 per share,

Ensysce Biosciences, Inc. (ENSC) experiences a decrease of 10.55% in the premarket. However, the last trading session closed at $4.55 with an increase of 48.21%. Treatment of First Cohort for Subjects in Clinical Study of its Next Generation Opioid, PF614 ENSC announced on 8th September 2021 that they have started the treatment of the first cohort of Study to Evaluate the Pharmacokinetics and Safety of Multiple-Ascending Oral Doses of PF614. PF614 is a trypsin-activated abuse prevention extended-release oxycodone prodrug (TAAP). Moreover, the TAAP chemical alteration inactivates the active component in Ensysce’s opioids products, including PF614. It also provides abuse-deterrent, resistance

Aethlon Medical, Inc. (AEMD) experiences an increase of 23.68% in the premarket without any particular reason. However, the last trading session concluded at $3.8 with an incline of 16.21%. First Quarter Financial Results 2021 AEMD announced the first quarter of 2021 financial results on 9th August 2021. According to the updates some of the highlights are as follows: The company has a cash balance of about $25.2 million as of June 30, 2021. AEMD generated approximately $17.5 million in net proceeds through the issuance of common stock. In the three months ending June 30, 2021, AEMD received about $115,000 in

Beyond Air Inc. (XAIR) stock prices were up by 6.91% as of the market closing on September 21st, 2021. This brought the price per share up to USD$12.54 at the end of the trading day. Subsequent premarket fluctuations saw the stock fall by 5.50%, bringing it down to USD$11.85. XAIR Stock’s Regulatory Update September 21st, 2021 saw XAIR stock provide an update on the global regulatory approval process for the LungFit PH system. The clinical-stage medical device and biopharmaceutical company successfully completed the Stage 1 Assessment Audit of its quality system. The audit was conducted by the Notified Body for